ArticleNPJ breast cancer2022

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Zheqi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.